Neuropathy Treatment Group's Supplement Claims Strike A Nerve In Industry Self-Regulation Review
Executive Summary
Neuropathy Treatment Group continues to make on its website numerous references to neuropathy and other diseases or conditions causing nerve pain. It pulled most of its challenged claims during a NAD review, and was advised to discontinue the remainder, too.
You may also be interested in...
P&G Introduces Nervive ‘Nerve Relief’ Supplements In US, Extending Line Acquired From Merck
P&G launches Nervive three-product line for nerve discomfort inspired by 50-year-old Neurobion brand marketed in Europe, Asia and Latin America. The products contain B-complex vitamins and alpha lipoic acid to promote blood flow.
CRN Ends Funding For Industry Self-Regulation Program Focused On Supplement Advertising
The trade group ends funding for National Advertising Division program launched in 2006 for increased focus on monitoring supplement claims, reviewing 360 in total. Separately, NAD launches an expedited challenge process aiming to conclude reviews in 20 business days.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.